Your Trusted Brand for Over 35 Years

Daily News

Investigators at Massachusetts Institute of Technology Release New Data on Osteoporosis (SIRT1 is a positive regulator of in vivo bone mass and a...

Drug Week

10-06-17

Investigators at Massachusetts Institute of Technology Release New Data on Osteoporosis (SIRT1 is a positive regulator of in vivo bone mass and a therapeutic target for osteoporosis)

By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Musculoskeletal Diseases and Conditions - Osteoporosis. According to news reporting originating in Cambridge, Massachusetts, by NewsRx journalists, research stated, "Overexpression or pharmacological activation of SIRT1 has been shown to extend the lifespan of mice and protect against aging-related diseases. Here we show that pharmacological activation of SIRT1 protects in two models of osteoporosis."

Financial supporters for this research include National Institutes of Health, Glenn Foundation for Medical Research (see also Musculoskeletal Diseases and Conditions - Osteoporosis).

The news reporters obtained a quote from the research from the Massachusetts Institute of Technology, "Ovariectomized female mice and aged male mice, models for post-menopausal and aging-related osteoporosis, respectively, show significant improvements in bone mass upon treatment with SIRT1 agonist, SRT1720. Further, we find that calorie restriction (CR) results in a two-fold upregulation of sirt1 mRNA expression in bone tissue that is associated with increased bone mass in CR mice. Reciprocally, SIRT1 whole-body knockout (KO) mice, as well as osteoblast and osteoclast specific KOs, show a low bone mass phenotype; though double knockout mice (containing SIRT1 deleted in both osteoblasts and osteoclasts) do not show a more severe phenotype."

According to the news reporters, the research concluded: "Altogether, these findings provide strong evidence that SIRT1 is a positive regulator of bone mass and a promising target for the development of novel therapeutics for osteoporosis."

For more information on this research see: SIRT1 is a positive regulator of in vivo bone mass and a therapeutic target for osteoporosis. Plos One, 2017;12(9):e0185236. (Public Library of Science - www.plos.org; Plos One - www.plosone.org)

Our news correspondents report that additional information may be obtained by contacting K. Zainabadi, Glenn Center for the Science of Aging, Dept. of Biology, Koch Institute, MIT, Cambridge, Massachusetts, United States. Additional authors for this research include C.J. Liu, A.LM. Caldwell and L. Guarente.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1371/journal.pone.0185236. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Therapy, Genetics, Cambridge, Osteoporosis, Pharmacology, Massachusetts, United States, Bone Research, North and Central America, Metabolic Bone Diseases and Conditions, Musculoskeletal Diseases and Conditions.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.